For Patients: Clinical Trials
Publications
Careers
Contact Us
Skip to main content
Toggle navigation
Investors & Media
Events & Presentations
Stock Information
News Releases
Financials
SEC filings
Quarterly & Annual Reports
IRS Tax Form 8937
Analyst Coverage
Corporate Governance
Governance Documents
Board Committee Composition
Shareholder Services
Derivative Settlement
Email Alerts
RSS Feeds
FAQ
- Frequently Asked questions
About Inovio
>
Purpose, Mission and Values
Leadership
Partnerships
DNA Medicines Technology
>
Optimized Plasmid Design and Delivery
DNA Medicines Explained
Technology Advances
Pioneering dMAb
TM
Science
DNA Medicines Pipeline
>
Investors & Media
Events & Presentations
Stock Information
News Releases
Financials
SEC filings
Quarterly & Annual Reports
IRS Tax Form 8937
Analyst Coverage
Corporate Governance
Governance Documents
Board Committee Composition
Shareholder Services
Derivative Settlement
Email Alerts
RSS Feeds
FAQ
- Frequently Asked questions
About Inovio
Mission and Values
Inovio Firsts
Leadership
Board of Directors
Scientific Advisory Board
CEO Corner
Partnerships
DNA Medicine Technology
Optimized Plasmid Design and Delivery
DNA Medicines Explained
Technology Advances
Pioneering dMAb
TM
Science
Our Focus: Serving Patients
Empowering Human Immunity
HPV-Associated Diseases
Immuno-Oncology
Infectious Diseases
Covid-19
DNA Medicine Pipeline
For Patients
Publications
Careers
Contact Us
INVESTORS
& MEDIA
Event Details
Inovio Pharmaceuticals Corporate Update
July 17, 2019
08:00 AM EST
Speaker(s):
Dr. J. Joseph Kim
,
President & CEO
Add to Calendar
Add to Apple Calendar
Add to Google Calendar
Add to Microsoft Outlook
Add to iCalendar
Webcast
Press Release
Transcript
(opens in new window)
PDF
56 KB
Quick Links
SEC Filings
Analyst Coverage
Investor Faq
Corporate Governance